Methylenedioxymethamphetamine inhibits mitochondrial complex I activity in mice: a possible mechanism underlying neurotoxicity

• Published in: British journal of pharmacology 2010-05, Vol.160 (2), p.233-245
• Main Authors: Puerta, Elena, Hervias, Isabel, Goñi‐Allo, Beatriz, Zhang, Steven F, Jordán, Joaquín, Starkov, Anatoly A, Aguirre, Norberto
• Format: Article
• Language: English
• Subjects: Animals; Antioxidants - pharmacology; Biological and medical sciences; complex I; Corpus Striatum - drug effects; Corpus Striatum - metabolism; Dopamine; Dopamine - metabolism; Ecstasy; Electron Transport Complex I - antagonists & inhibitors; Free radicals; Free Radicals - metabolism; Hallucinogens - toxicity; lipoic acid; Male; MDMA; Medical sciences; Mice; mitochondria; Mitochondria - drug effects; Mitochondria - metabolism; N-Methyl-3,4-methylenedioxyamphetamine - toxicity; Neurotoxicity; Neurotoxicity Syndromes - etiology; Nitric oxide; Oxidative stress; Oxidative Stress - drug effects; Pharmacology. Drug treatments; Research Papers with Commentaries; Rodents; Thioctic Acid - pharmacology
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1111/j.1476-5381.2010.00663.x

Background and purpose:  3,4‐methylenedioxymethamphetamine (MDMA) causes a persistent loss of dopaminergic cell bodies in the substantia nigra of mice. Current evidence indicates that such neurotoxicity is due to oxidative stress but the source of free radicals remains unknown. Inhibition of mitochondrial electron transport chain complexes by MDMA was assessed as a possible source. Experimental approach:  Activities of mitochondrial complexes after MDMA were evaluated spectrophotometrically. In situ visualization of superoxide production in the striatum was assessed by ethidium fluorescence and striatal dopamine levels were determined by HPLC as an index of dopaminergic toxicity. Key results:  3,4‐methylenedioxymethamphetamine decreased mitochondrial complex I activity in the striatum of mice, an effect accompanied by an increased production of superoxide radicals and the inhibition of endogenous aconitase. α‐Lipoic acid prevented superoxide generation and long‐term toxicity independent of any effect on complex I inhibition. These effects of α‐lipoic acid were also associated with a significant increase of striatal glutathione levels. The relevance of glutathione was supported by reducing striatal glutathione content with L‐buthionine‐(S,R)‐sulfoximine, which exacerbated MDMA‐induced dopamine deficits, effects suppressed by α‐lipoic acid. The nitric oxide synthase inhibitor, NG‐nitro‐L‐arginine, partially prevented MDMA‐induced dopamine depletions, an effect reversed by L‐arginine but not D‐arginine. Finally, a direct relationship between mitochondrial complex I inhibition and long‐term dopamine depletions was found in animals treated with MDMA in combination with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine. Conclusions and implications:  Inhibition of mitochondrial complex I following MDMA could be the source of free radicals responsible for oxidative stress and the consequent neurotoxicity of this drug in mice. This article is commented on by Moncada, pp. 217–219 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476‐5381.2010.00706.x and to view related papers in this issue by Pravdic et al. and Kurz et al. visit http://dx.doi.org/10.1111/j.1476‐5381.2010.00698.x and http://dx.doi.org/10.1111/j.1476‐5381.2010.00656.x